Jim Simons Adaptimmune Therapeutics PLC Call Options Transaction History
Renaissance Technologies LLC
- $70.6 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADAP
# of Institutions
64Shares Held
42MCall Options Held
139KPut Options Held
144K-
Long Focus Capital Management, LLC San Juan, PR18.6MShares$557,3340.1% of portfolio
-
Ubs Group Ag6.67MShares$200,0200.0% of portfolio
-
Morgan Stanley New York, NY3.67MShares$109,9810.0% of portfolio
-
Jane Street Group, LLC New York, NY2.81MShares$84,1600.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.49MShares$44,5540.0% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $4.9M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...